Semaglutide, lipid-lowering drugs, and NAFLD

Niki Katsiki¹, Vasilios G Athyros¹, Asterios Karagiannis¹, Dimitri P Mikhailidis²

Affiliations

¹ Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
² Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London, London NW3 2QG, UK. Electronic address: mikhailidis@aol.com.

PMID: 28434490
DOI: 10.1016/S2213-8587(17)30109-2

Comment

Semaglutide, lipid-lowering drugs, and NAFLD

Niki Katsiki et al. Lancet Diabetes Endocrinol. 2017 May.

. 2017 May;5(5):329-330.

doi: 10.1016/S2213-8587(17)30109-2.

Authors

Niki Katsiki¹, Vasilios G Athyros¹, Asterios Karagiannis¹, Dimitri P Mikhailidis²

Affiliations

¹ Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
² Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London, London NW3 2QG, UK. Electronic address: mikhailidis@aol.com.

PMID: 28434490
DOI: 10.1016/S2213-8587(17)30109-2

No abstract available

PubMed Disclaimer

Comment in

Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply.
Sorli C. Sorli C. Lancet Diabetes Endocrinol. 2017 May;5(5):330. doi: 10.1016/S2213-8587(17)30110-9. Lancet Diabetes Endocrinol. 2017. PMID: 28434491 No abstract available.

Comment on

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Sorli C, et al. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. doi: 10.1016/S2213-8587(17)30013-X. Epub 2017 Jan 17. Lancet Diabetes Endocrinol. 2017. PMID: 28110911 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Semaglutide, lipid-lowering drugs, and NAFLD

Affiliations

Semaglutide, lipid-lowering drugs, and NAFLD

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical